Roggwil, February 28, 2022 – As reported in January 2022, work is being intensified on the expansion of the production of the tinniwell. This week, production of the tinniwell will commence at another contract manufacturer. The background is to ensure the supply of patients with the tinniwell. After the delivery of this series, a framework agreement for the production of an additional 2,000 units with this manufacturer is being pursued.

++ About Resaphene Suisse AG

Resaphene Suisse AG, based in Roggwil, Switzerland, is a medical technology company founded in 2015, which has been selling a tinnitus therapy device under the name tinniwell since 2016.

++ Contact for inquiries:

Resaphene Suisse AG


Ms. Anke Rauterkus (Chief Executive Officer)

Bahnhofplatz 5

9322 Egnach


Switzerland

T. +41 714500668


a.rauterkus@resaphene.ch